HISTOPATHOLOGICAL GRADE AND RESPONSE TO CHEMOTHERAPY IN ADVANCED SOFT-TISSUE SARCOMAS

被引:6
作者
DAUGAARD, S
VONGLABBEKE, M
SCHIODT, T
MOURIDSEN, HT
机构
[1] RIGSHOSP,DEPT PATHOL,DK-2100 COPENHAGEN,DENMARK
[2] RIGSHOSP,DEPT ONCOL,DK-2100 COPENHAGEN,DENMARK
[3] EORTC DATA CTR,BRUSSELS,BELGIUM
关键词
D O I
10.1016/S0959-8049(05)80414-9
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
In a retrospective analysis, we evaluated the possible significance of histopathological grade with regard to response to chemotherapy in advanced soft tissue sarcomas. In three EORTC protocols, the same dose-schedule was used for patients randomised to treatment with doxorubicin as a single agent (75 mg/m2 every third week). The submitted pathological slides from 94 of these patients were reviewed and graded. The following parameters were subjectively graded (+/++/+++): nuclear pleomorphism, necrosis, cellularity and vascularity. Mitoses were counted in 20 high-power fields, and a final grade assigned as I, II, IIIA or IIIB. The results were tested both with regard to response (complete response + partial response vs. no change + progressive disease) and survival. However, no statistically significant correlations or trends could be demonstrated. Thus, tumour grade, although a prognostic factor by itself, does not seem to be able to predict response to chemotherapy in the advanced stage.
引用
收藏
页码:811 / 813
页数:3
相关论文
共 29 条
[1]   CHEMOTHERAPY OF ADVANCED SOFT-TISSUE SARCOMAS [J].
ANTMAN, KH ;
ELIAS, AD .
SEMINARS IN SURGICAL ONCOLOGY, 1988, 4 (01) :53-58
[2]   REVIEW OF THE CLINICAL-TRIALS ACTIVITY OF THE SOFT-TISSUE AND BONE SARCOMA GROUP OF THE EUROPEAN ORGANIZATION FOR RESEARCH AND TREATMENT OF CANCER [J].
BRAMWELL, VHC ;
SANTORO, A ;
ROUESSE, J ;
MOURIDSEN, H ;
STEWARD, W ;
VANOOSTEROM, A ;
SOMERS, R ;
BUESA, J ;
MULDER, J ;
SCHUTTE, J ;
PINEDO, H ;
BLACKLEDGE, G ;
WAGENER, T ;
DOMBERNOWKY, P .
SEMINARS IN SURGICAL ONCOLOGY, 1988, 4 (01) :45-52
[3]   CARMINOMYCIN VS ADRIAMYCIN IN ADVANCED SOFT-TISSUE SARCOMAS - AN EORTC RANDOMIZED PHASE-II STUDY [J].
BRAMWELL, VHC ;
MOURIDSEN, HT ;
MULDER, JH ;
SOMERS, R ;
VANOOSTEROM, AT ;
SANTORO, A ;
THOMAS, D ;
SYLVESTER, R ;
MARKHAM, D .
EUROPEAN JOURNAL OF CANCER & CLINICAL ONCOLOGY, 1983, 19 (08) :1097-1104
[4]  
BUI NB, 1985, CANCER CHEMOTH PHARM, V15, P82
[5]  
COINDRE JM, 1986, CANCER, V58, P306, DOI 10.1002/1097-0142(19860715)58:2<306::AID-CNCR2820580216>3.0.CO
[6]  
2-7
[7]  
COSTA J, 1984, CANCER, V53, P530, DOI 10.1002/1097-0142(19840201)53:3<530::AID-CNCR2820530327>3.0.CO
[8]  
2-D
[9]  
GRAEM N, 1979, ACTA PATH MICRO IM A, V87, P375
[10]  
HENSON DE, 1988, ARCH PATHOL LAB MED, V112, P1091